R. Hui Et Al. , "Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes," JOURNAL OF THORACIC ONCOLOGY , vol.13, no.4, 2018
Hui, R. Et Al. 2018. Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes. JOURNAL OF THORACIC ONCOLOGY , vol.13, no.4 .
Hui, R., Ozguroglu, M., Villegas, A., Daniel, D., Vicente, D., Murakami, S., ... Ryden, A.(2018). Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes. JOURNAL OF THORACIC ONCOLOGY , vol.13, no.4.
Hui, R. Et Al. "Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes," JOURNAL OF THORACIC ONCOLOGY , vol.13, no.4, 2018
Hui, R. Et Al. "Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes." JOURNAL OF THORACIC ONCOLOGY , vol.13, no.4, 2018
Hui, R. Et Al. (2018) . "Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes." JOURNAL OF THORACIC ONCOLOGY , vol.13, no.4.
@article{article, author={R. Hui Et Al. }, title={Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2018}